Eli Lilly vs Novo Nordisk: Who's Winning the Weight-Loss Drug Race?

Eli Lilly is winning the overall race, but Novo Nordisk is winning the newest one. As of the week reported September 11, 2026, Lilly’s tirzepatide (Mounjaro and Zepbound) held about 57% of the total US GLP-1 market, up from about 49.5% a year earlier, while Novo’s semaglutide (Ozempic and Wegovy) stayed relatively flat at about 37%, according to IQVIA data cited by Citi ^[1]. In the obesity segment alone, the split has held steady at roughly 60% Lilly to 40% Novo through mid-2026 ^[1]. Lilly CEO David Ricks put it bluntly on CNBC’s Squawk Box on February 4, 2026: “We’re the market leader in both diabetes and obesity now” ^[4].

The one place the leaderboard flips is pills. Novo’s Wegovy pill pulled about 183K weekly prescriptions in the most recent reporting period, versus about 47.5K for Lilly’s Foundayo ^[1]. For patients, the practical effects of this fight show up less in market share and more in price and coverage: company websites now list starting prices of $149 to $299 per month, down from the roughly $1,000 monthly pharmacy retail prices after the 2021 and 2023 launches ^[6], and the Medicare GLP-1 Bridge program began covering certain weight-loss drugs on July 1, 2026 ^[1].

Who is ahead on prescriptions right now?

Lilly leads on injections, and it is not close. Zepbound reached a little under 772,000 weekly prescriptions in the September 4, 2026 update, up 1.6%, while total Wegovy (pill plus injection) came in at 513,500, up 2.7% ^[1]. Among injectable incretins, Lilly says its drugs now draw three out of four new patient starts ^[3].

All weekly prescription figures come from IQVIA data cited in Citi and Jefferies analyst notes, which are estimates rather than a full count. Citi has flagged that IQVIA may be missing Foundayo prescriptions filled through telehealth channels, so Foundayo’s true numbers could be higher than the reported 47.5K ^[1].

The overall market is growing again. Total GLP-1 prescriptions rose 5.4% over the trailing four weeks, compared with a 6.8% decline a year earlier. Citi attributes that 12-point swing to the arrival of oral GLP-1 drugs, which appear to be pulling in new patients rather than only shifting people off injections ^[1].

How do the companies’ sales compare?

Lilly’s quarterly numbers are much larger and growing much faster. In the second quarter of 2026, Lilly reported worldwide revenue of $23.0 billion, up 48% year over year, driven by a 60% increase in volume that was partly offset by a 13% drop in realized prices ^[2]. US revenue rose 33% to $14.4 billion ^[2]. Mounjaro brought in $9,943 million, up 91%, and Zepbound brought in $4,928 million, up 46% ^[2]. The quarter beat analyst consensus of $20.6 billion ^[3].

Novo’s second quarter told a different story. The Wegovy pill generated 3.22 billion Danish kroner (about $497 million), up from 2.26 billion kroner (about $354 million) in the first quarter ^[3]. Ozempic posted about $4.8 billion in sales, up 3%, and injectable Wegovy about $3.0 billion, up 1% ^[3]. One caution when comparing the two companies: Novo reports in Danish kroner and Lilly in US dollars, so currency movements and different reporting bases affect any side-by-side growth comparison.

Second quarter 2026	Eli Lilly	Novo Nordisk
Total revenue	$23.0 billion, up 48% [2]	Not directly comparable (reports in kroner)
Lead diabetes drug	Mounjaro $9,943M, up 91% [2]	Ozempic ~$4.8B, up 3% [3]
Lead obesity injection	Zepbound $4,928M, up 46% [2]	Wegovy injection ~$3.0B, up 1% [3]
Obesity pill	Foundayo $98M [2]	Wegovy pill ~$497M [3]

The full-year outlooks diverge the same way. Lilly raised its 2026 revenue guidance to $85.0 billion to $87.0 billion, with the midpoint up from $83.5 billion; hitting that midpoint would mean about 32% growth over its $65.2 billion in 2025 revenue ^{[2] [3]}. Back on February 4, 2026, Lilly’s initial 2026 guidance of $80 billion to $83 billion had already beaten the $77.62 billion LSEG consensus ^[4]. The day before, on February 3, 2026, Novo guided for 2026 sales and operating profit to decline 5% to 13%, citing falling US prices and loss of exclusivity in China, Brazil and Canada ^[4].

Why is Novo’s pill outselling Lilly’s pill?

Timing and brand power. The FDA approved the Wegovy pill on December 22, 2025, making it the first oral GLP-1 for obesity in the US, and it launched January 5, 2026 ^{[8] [3]}. Foundayo (orforglipron) was approved April 1, 2026 and reached the US market that April, roughly three months behind ^{[3] [5]}. That first-mover gap has been cited as a factor in Novo’s faster ramp ^[3].

Novo also started with a huge installed base: about 3.2 million people in the US had already been prescribed Wegovy when the pill was approved ^[8]. The company launched direct-to-consumer advertising for the pill in early January 2026 ^[4]. Lilly, by contrast, secured commercial access across all three major pharmacy benefit managers in June 2026 and only then began broad direct-to-consumer marketing, as Ricks explained on the Q2 earnings call ^[1].

The launch curves show the gap. The Wegovy pill hit 50,000 weekly prescriptions in just under three weeks ^[4], and reached about 57K by week 6 of its launch ^[1]. Foundayo passed 40,000 weekly scripts (40,862) only at week 20 of its launch ^[1]. By an August 28, 2026 Jefferies note, Foundayo’s share of new prescriptions in the oral obesity market was 21.5% ^[1].

The pill boom also appears to be expanding the market rather than just moving people off injections. IQVIA reported that within eight weeks of launch, oral Wegovy captured about one-third of new-to-brand prescriptions, with the majority of volume flowing through cash-pay channels, and that about two-thirds of that volume came from users new to any GLP-1 therapy ^[5].

Foundayo brought in $98 million worldwide in the second quarter of 2026, including $67 million in the US, which Leerink analyst David Risinger called a disappointment ^{[2] [3]}. He noted the drug’s $31 million in United Arab Emirates sales “bodes well for Foundayo’s global potential” ^[3]. Lilly’s Ilya Yuffa said in August 2026 that volume had doubled from a month earlier and that new starts were coming in at “nearly around one out of four” ^{[1] [3]}.

How do the two pills actually differ?

The biggest day-to-day difference is how you take them. The Wegovy pill is a peptide, so it comes with rules: no more than 4 ounces of water with the dose, then wait 30 minutes before eating or drinking anything else ^[4]. Foundayo is a small molecule that is absorbed more easily and has no fasting or water restrictions ^{[4] [1]}.

On efficacy, the Wegovy pill’s approval rested on the OASIS 4 trial: a 64-week study of 307 adults with obesity or overweight plus at least one weight-related condition, but no diabetes ^[8]. People taking Wegovy pill 25 mg lost about 17% (16.6%) of body weight if all patients stayed on treatment, versus about 3% (2.7%) on placebo; counting everyone regardless of adherence, the figures were about 14% (13.6%) versus about 2% (2.4%) ^[8].

Novo CEO Mike Doustdar has claimed his company has “the most efficacious weight-reduction pill that there is” ^[4]. CNBC reported that Lilly’s pill appears slightly less effective based on separate studies, but that is a cross-trial comparison, not a head-to-head finding ^[4]. The Wegovy pill also carries an indication to reduce the risk of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease ^[8].

Why did Lilly’s injections pull ahead in the first place?

A Lilly-run head-to-head trial in 2024 found Zepbound produced more weight loss than Wegovy ^[4]. Risinger has said tirzepatide is “superior” to semaglutide on both effectiveness and tolerability, and that this is what is driving Lilly’s market share gain ^[4]. Lilly’s early move into direct-to-consumer sales has also been cited as a structural advantage ^[4].

Patents matter too. Ricks said tirzepatide should stay protected in major markets into “the back half of the 2030s,” while Novo has said expiring patents in some international markets pose a challenge ^[4].

What is each company working on next?

Lilly’s next big asset is retatrutide, a triple agonist. The company reported positive data from three additional Phase 3 obesity trials alongside its Q2 2026 results and says its clinical data package is now complete for obesity, obstructive sleep apnea, and knee osteoarthritis pain, with a US Biologics License Application planned for the first quarter of 2027 ^[2]. IQVIA expects retatrutide on the market in the 2027 to 2028 era ^[5]. Lilly has also submitted orforglipron for type 2 diabetes in the US ^[2].

Novo’s next-generation asset is CagriSema, a combination of semaglutide and cagrilintide ^[5]. Beyond its own pipeline, Lilly spent heavily in Q2 2026: it completed acquisitions of Orna, Ajax, Centessa and Kelonia, took on $2.8 billion in acquired IPR&D charges, agreed to acquire AtaiBeckley, and committed an additional $4.5 billion to expand Indiana manufacturing ^[2].

Novo laid out its own plans at a September 21, 2026 strategy event, setting ambitions to launch more than five potential multi-blockbuster drugs by 2030, but shares fell about 8% as Citi said the announcements “offered little change” to its forecast of mid-single-digit annual growth until 2030 and reiterated its neutral rating on the stock ^{[28] [29]}. Lilly shares are up 58% over the past 12 months, while Novo’s have declined 34% over the past year ^{[28] [27]}. The next day, CEO Mike Doustdar said it would be “more obvious” to imagine Novo “making more deals in areas outside of the core than in the core,” pointing to blood and endocrine disorders, liver disease and cardiovascular disease ^[27].

How big is the obesity drug market, really?

IQVIA’s ForecastLink put global obesity medicine sales at $66 billion (list price) in 2025 and forecasts $92 billion in 2026, with a wide range of $105 billion to $200 billion from 2027 onward ^[5]. Ricks said in February 2026 that 20 to 25 million patients are currently taking the two companies’ medicines ^[4].

Forecasts for later in the decade have swung sharply, and they are analyst opinions, not facts. As reported by Reuters on February 2, 2026, Goldman Sachs’ estimate for global obesity drug sales by 2030 stood at $105 billion, down from earlier forecasts of $130 billion, based on steeper price erosion ^[6]. Jefferies cut its peak forecast by 20% in January 2026, to $80 billion from its 2023 estimate of over $100 billion by the early 2030s ^[6]. IQVIA pushed its roughly $130 billion forecast out to 2034 from 2028 ^[6]. HSBC’s Rajesh Kumar still sees more than $120 billion by the end of 2030, and Pfizer CEO Albert Bourla said in January 2026 he expects $150 billion a year by 2030 ^[6].

A separate Goldman note, reported by ZeroHedge, raised the 2030 anti-obesity forecast to $114 billion from a prior $101 billion, which Goldman had made in December 2025, citing oral adoption, demand outside the US, and better affordability ^[7]. The two Goldman figures do not line up into a single sequence — the February 2026 Reuters report shows a $105 billion estimate against a $130 billion prior, while the other note shows $114 billion against a $101 billion prior — and the sources do not reconcile them ^{[6] [7]}. In the $114 billion update, Goldman projected orals at 40% ($46 billion) of the 2030 market, peak Wegovy pill sales of $17.4 billion, Foundayo 2030 sales of $22 billion, and the two companies together holding 82% of global GLP-1 share by the end of the decade ^[7].

What has the rivalry done to prices and coverage?

Prices have fallen a lot. After the launches of Wegovy in 2021 and Zepbound in 2023, pharmacy retail prices ran about $1,000 per month; company websites now list starting prices of $149 to $299 ^[6]. The Wegovy pill’s 1.5 mg starting dose was available in early January 2026 for $149 per month with savings offers ^[8]. Both companies struck “most favored nation” pricing deals with the Trump administration in November 2025 to cut obesity and diabetes drug costs ^[4].

Coverage has expanded too. The Medicare GLP-1 Bridge program went live July 1, 2026, covering certain weight-loss drugs, including Foundayo, at a $50 monthly copay for Part D beneficiaries ^[1]. Ricks said Medicare coverage opens access to 40 million beneficiaries ^[4]. Goldman has modeled a potential 17 million-patient Medicare opportunity over time and $2.6 billion in Medicare-channel obesity sales in 2026, mostly skewed toward injectables ^[7].

The price pressure shows up in the financials. Lilly’s realized prices fell 13% worldwide in Q2 2026; US realized prices fell 3% as reported, or about 9% excluding adjustments to rebate and discount estimates ^[2]. Lilly guided to a global pricing decline in the low- to mid-teens percentage range for 2026 ^[4]. Goldman lowered its US direct-to-consumer price assumption by 20%, to $287 from $355 ^[7]. A Jefferies note from August 21, 2026 observed that Wegovy has been relatively flat since the Medicare Bridge program began ^[1].

Who else is entering the market?

IQVIA expects the market to cease being a duopoly and to be actively contested by multiple major pharmaceutical players ^[5]. Pfizer won the 2025 bidding war against Novo for Metsera, paying up to $10 billion ^{[5] [6]}. Amgen is expected to bring MariTide, a once-monthly dual-action injectable, in the 2027 to 2028 era ^[5]. Roche entered through its 2024 acquisition of Carmot, and Boehringer Ingelheim is coming with survodutide, a glucagon/GLP-1 also positioned for MASH ^[5]. AstraZeneca announced a partnership with China’s CSPC in 2026 ^[5].

Generics are already arriving outside the US. Semaglutide lost exclusivity in India on March 20, 2026, and exclusivity losses in 2026 across India, China, Brazil, Turkey and Canada affect markets holding 38% of adults with obesity globally ^[5]. IQVIA counts 74 Chinese developers and CDMOs working on generic semaglutide ^[5]. In China itself, Innovent launched mazdutide (Xinermei) in 2025 and Sciwind launched ecnoglutide in 2026 ^[5].

Does any of this change which drug is right for me?

Market share is a scoreboard for investors, not a guide for choosing a medicine. What actually differs for patients, according to IQVIA’s analysis, is increasingly about tolerability, outcomes beyond weight loss, dosing route and frequency, and muscle and bone preservation, rather than weight loss alone ^[5]. Tolerability is the most-cited reason patients stop GLP-1 treatment, and persistence varies by brand and country ^[5]. Label expansions, such as the cardiovascular benefit for Wegovy and the sleep apnea indication for Mounjaro and Zepbound, are where promotional emphasis is rising fastest ^[5].

For cost, coverage status matters more than market share: PBM access and Medicare Bridge eligibility differ drug by drug ^[1]. Questions about which medicine fits a particular situation belong with a clinician and insurer, not with a prescription tracker.

Sources

1. Fierce Pharma. The Oral GLP-1 Tracker: Novo’s Wegovy pill, Lilly’s Foundayo continue prescription climb. September 11, 2026.
2. Eli Lilly and Company. Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress. August 5, 2026.
3. Fierce Pharma. Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom. August 5, 2026.
4. CNBC. Eli Lilly gaining in GLP-1 market over Novo Nordisk, earnings show. February 4, 2026.
5. IQVIA. The outlook for obesity from 2026 to 2030. April 21, 2026.
6. Reuters. Obesity market sales potential tightens as Novo and Lilly enter new era. February 2, 2026.
7. ZeroHedge. Goldman hikes obesity drug market forecast as oral GLP-1s go mass market.
8. PR Newswire. FDA approves Novo Nordisk’s Wegovy pill, the first and only oral GLP-1 for weight loss in adults.
9. Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 1, 2026.
10. PR Newswire. FDA approves Novo Nordisk’s new Wegovy HD injection, delivering the highest weight loss to date for a Wegovy injection, adding to its already expansive clinical profile. March 19, 2026.
11. PR Newswire. Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management.
12. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.
13. Reuters. Exclusive: Novo Nordisk cuts hit production line jobs at key US plant, posts show. October 7, 2025.
14. Novo Nordisk. Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio. October 9, 2025.
15. CNBC. Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits. November 8, 2025.
16. The White House. Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients. November 6, 2025.
17. KFF. Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford. November 14, 2025.
18. Reuters. AstraZeneca strikes deal for up to $18.5 billion to license weight-loss drugs from China’s CSPC. January 30, 2026.
19. BigGo Finance. Novo Nordisk CFO Knudsen: Oral Wegovy Drives Market Expansion With 80% of Patients New to Obesity Drugs.
20. CNBC. India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top. March 23, 2026.
21. Novo Nordisk. News & Company Announcement archive.
22. LillyDirect. Foundayo (orforglipron): Now available.
23. NovoCare. Wegovy (semaglutide) cost, coverage, and savings resources.
24. PR Newswire. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines), building on continued efforts to expand access.
25. HCPLive. CagriSema Demonstrates Weight Loss, Fails to Achieve Primary Endpoint Compared to Tirzepatide. February 23, 2026.
26. MPR. REDEFINE 4: CagriSema Weight Loss Results Compared With Tirzepatide.
27. CNBC. Novo defends diversification push as CEO eyes deals beyond GLP-1. September 22, 2026.
28. CNBC. Novo Nordisk CEO on rebuilding investor trust after backlash. September 24, 2026.
29. STAT. Novo details new strategy in obesity, other disease areas. September 21, 2026.